PER® Congress on Hematologic Malignancies (Winter Hematology®) | Conference

Dr. Park on Challenges With CAR T-Cell Therapies in AML

March 1st 2019

Jae H. Park, MD, discusses a particular challenge he sees in using CAR T-cell therapies in patients with acute myeloid leukemia.

BCMA-Directed CAR T-Cell Therapy Makes Strong Entrance in Myeloma

March 1st 2019

B-cell maturation antigen-specific chimeric antigen receptor T-cell therapy is delivering impressive results in multiple myeloma, demonstrating durable responses and acceptable toxicities.

Dr. Andre Goy Explains Marginal Zone Lymphoma

March 31st 2016

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses marginal zone lymphoma.

Dr. Byrd on Ibrutinib's Impact on Treatment Landscape in CLL

March 21st 2016

John Byrd, MD, director of the Division of Hematology, Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, discusses the RESONATE 2 study, which looked at ibrutinib versus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia (CLL).

Dr. Jagannath on Next-Generation Approaches in Multiple Myeloma

March 21st 2016

Sundar Jagannath, MD, professor of Medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses upcoming agents in multiple myeloma.

Newer Agents, Combinations Being Studied for Targeted Therapies in CLL

March 20th 2016

Targeted agents, particularly ibrutinib and idelalisib, are becoming increasingly important in the treatment of chronic lymphocytic leukemia, and have replaced chemotherapy in many settings.

CAR T-cells Rapidly Evolving as Cancer Therapies

March 20th 2016

Chimeric antigen receptor-modified T-cell therapies have demonstrated durable complete responses for patients with relapsed/refractory B-cell acute lymphoblastic leukemia; however, several questions remain regarding their optimal use and applicability outside of this disease.

Dr. Susan O'Brien on Next-Generation Small Molecules in CLL

March 20th 2016

Susan O’Brien, MD, Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center and Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses upcoming agents in chronic lymphocytic leukemia (CLL).

Dr. John Leonard on Treatment Options for Relapsed Follicular Lymphoma

March 20th 2016

John Leonard, MD, medical oncology, at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses follicular lymphoma treatment considerations. Treatment options include rituximab and bendamustine, which have been around for sometime, as well as newer agents like obinutuzumab, says Leonard.

Extended Phase III Data Illuminates Ibrutinib Survival Benefit in CLL

March 20th 2016

Extended follow-up data continue to demonstrate the efficacy and tolerability of ibrutinib in previously treated patients with chronic lymphocytic leukemia, including those with high-risk gene mutations and prognostic features.

Potential of Immuno-Oncology Continues to Expand

March 19th 2016

Immuno-oncology has advanced rapidly, with the introduction of immune checkpoint inhibition and effective adoptive T-cell therapies. As these agents rush through development, several questions remain regarding the optimal patients for treatment and the next steps for further improving outcomes.

Genomics Help Customize Therapy in Non-Hodgkin Lymphoma

March 19th 2016

With the R-CHOP chemotherapy regimen considered the backbone of therapy for treatment-naïve patients with non-Hodgkin lymphoma, researchers are now delving further into the genome to pave the way for therapeutic improvements.

Dr. Jennifer Brown on RESONATE 2 Trial in CLL

March 19th 2016

Jennifer Brown MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses RESONATE 2 and frontline ibrutinib use in patients with chronic lymphocytic leukemia (CLL).

Dr. Michael Williams on Lenalidomide Plus Rituximab in First- Line MCL

March 19th 2016

Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses frontline lenalidomide (Revlimid) and rituximab (Rituxan) in mantle cell lymphoma (MCL).

Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL

March 19th 2016

A multitude of PI3K and BTK inhibitors are currently in development that offer distinct advantages over existing treatments for patients with relapsed chronic lymphocytic leukemia.

Dr. Sagar Lonial on Early Treatment Versus Observation for Smoldering Multiple Myeloma

March 18th 2016

Sagar Lonial, MD, professor and chair, department of Hematology & Medical Oncology, Emory University School of Medicine, Chief Medical Officer, Winship Cancer Institute of Emory University, discusses treatment for smoldering multiple myeloma.

Novel Agents on Horizon for Follicular Lymphoma

March 18th 2016

A host of novel agents are on the horizon that could further improve the long-term outcomes experienced by patients with follicular lymphoma, particularly those with relapsed or refractory disease.

Kareem Abdul-Jabbar Discusses Living With CML

March 18th 2016

Kareem Abdul-Jabbar, retired NBA player for the Milwaukee Bucks and the Los Angeles Lakers, discusses his experience with chronic myeloid leukemia‎ (CML) at the 20th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas and Myeloma, held March 18.

Frontline Ibrutinib Highly Effective Across Subgroups for Elderly Patients With CLL/SLL

March 18th 2016

Frontline treatment with ibrutinib reduced the risk of progression or death by 84% compared with single-agent chlorambucil for elderly patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Frontline Therapy Rapidly Evolving for Multiple Myeloma

March 18th 2016

Shaji Kumar, MD, discusses how the phase III SWOG S0777 study, which investigated the combination of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone, significantly changed the frontline treatment paradigm for patients with multiple myeloma

NEXT PAGE
PREVIOUS PAGE